Safety of tepotinib plus osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
C. K. Liam,T. M. Kim,J-J. Yang, C. Huang,P-J. Voon, L. M. Tho, Q. Zhou, J. Wang, H. Hayashi, D. S. W. Tan, P. Danchaivijitr, V. N. Nguyen,K. H. Wong,J. C-H. Yang, X. Le, B. Ellers-Lenz, N. Karachaliou, V. Ghori, K. Berghoff,Y-L. Wu ANNALS OF ONCOLOGY（2023）
AI 理解论文
溯源树
样例
